Annovis Bio, Inc. (NASDAQ:ANVS) saw director Michael B. Hoffman make an acquisition of common stock on May 20, 2026. The transaction involved Mr. Hoffman purchasing common shares totaling $142,778. These purchases were executed across a range of prices, specifically between $1.75 and $1.8999 per share.
The total number of shares acquired through this activity amounted to 76,344 shares. Following these recent acquisitions, Mr. Hoffman's direct holdings of Annovis Bio common stock increased, bringing his personal stake to 3,364,883 shares. Furthermore, he maintains an indirect interest totaling 223,357 shares via The 2024 Hoffman Family Trust, where he retains both voting and investment power.
This insider purchase occurred while the stock was trading at $2.15. This price point reflects a significant decline of 43% over the preceding six months. At present, Annovis Bio maintains a market capitalization valued at $74.14 million. From an analytical standpoint provided by InvestingPro, which furnishes comprehensive financial metrics and Fair Value estimates for thousands of stocks, Annovis Bio currently appears to be slightly undervalued when compared against its assessed Fair Value.
Beyond the director's buying activity, the company has reported several major corporate updates that provide context to the current valuation. Most notably, Annovis Bio Inc. announced the pricing for a $15 million public offering. This offering entails 7,895,000 shares of common stock and warrants sufficient to purchase up to 7,105,500 additional shares.
The combined price set for this offering is $1.90 per share. Furthermore, each warrant purchased through the deal has an exercise price of $2.25 per share and is scheduled to expire six years after its issuance date. This announcement followed the company's proposal for both an underwritten public offering of common stock and accompanying warrants, which are intended to be issued separately but acquired together.
In parallel developments that may influence investor perception, Annovis Bio also announced positive outcomes from a Phase 2/3 clinical trial involving buntanetap. This study was conducted on patients diagnosed with mild to moderate Alzheimer’s disease and demonstrated statistically significant, dose-dependent improvements in cognition among those identified as pTau217 biomarker-positive patients.
These compelling findings were further validated by publication in the peer-reviewed journal *Nature NPJ Dementia*. The published data highlighted measurable cognitive improvements observed within the study participants, adding a layer of scientific validation to the company's pipeline.
Risks
- Market Price Decline
- Dilution from Public Offering
- Future Performance Reliance
More from Insider Trading
Risks
- Market Price Decline
- Dilution from Public Offering
- Future Performance Reliance